Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT04203485 · UNKNOWN
Trial details
- NCT number
- NCT04203485
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-15
- Primary completion
- 2022-03-31
- Enrollment
- 762
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.